STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

PR Newswire
2 min read
0
In this article:

LAKE FOREST, Calif., March 20, 2024 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1

(Graphic: STAAR Surgical)
(Graphic: STAAR Surgical)

"EVO ICL is the next logical step in refractive innovation with clear differentiators in patient outcomes and satisfaction. Our lens-based technology is ushering in the next generation of vision correction by helping to free patients from the struggle of daily contacts and eyeglasses."

"We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens milestone," said Tom Frinzi, President and CEO of STAAR Surgical. "EVO ICL is the next logical step in refractive innovation with clear differentiators in patient outcomes and satisfaction. Our lens-based technology is ushering in the next generation of vision correction by helping to free patients from the struggle of daily contacts and eyeglasses."

EVO ICL is an implantable lens designed to correct a wide range of vision correction needs, including myopia with and without astigmatism, through a minimally invasive procedure. The EVO ICL lens is implanted between the iris (the colored part of the eye) and the natural crystalline lens in a quick and safe procedure. It's biocompatible and does not remove corneal tissue, so it works with the natural eye, and the lens implant is removable by a surgeon, if desired. Myopia (nearsightedness) is the most common refractive visual error and is a global epidemic that is expected to impact over half the world's population by 2050.2

1 EVO ICL accounts for approximately 2.5 million of the 3 million total ICLs sold.

2 Ophthalmology 2016;123:1036-1042 © 2016 by the American Academy of Ophthalmology.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL," which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA, and Nidau, Switzerland. For more information, please visit the Company's website at www.staar.com

 

CisionCision
Cision

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/staar-surgical-celebrates-three-million-implantable-collamer-lenses-302094261.html

SOURCE STAAR Surgical

Advertisement

Recommended Stories

  • Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

    Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.

  • Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

    Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

  • Pfizer Receives FDA Approval for Bleeding Disorder Treatment

    Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.

  • Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again

    Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.

  • Pioneer Institute study finds IRA discourages non-opioid drug innovation

    The IRA adds another hurdle to an already challenging research landscape, according to a study from the Pioneer Institute.

  • FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

    Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves

  • The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says

    With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.

  • 2 Fantastic Growth Stocks to Buy Right Now

    Don't overlook these high-growth businesses.

  • The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

    The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.

  • How Can I Afford Nursing Home Care?

    Nursing home care can be extremely expensive. According to Genworth's 2021 Cost of Care Survey, the median monthly cost of a private room is a nursing home is $9,034. That's over $100,000 a year! And most people will need nursing … Continue reading → The post How to Pay for Nursing Home Care appeared first on SmartAsset Blog.